NKTR - ネクタ―・セラピュ―ティクス （Nektar Therapeutics） ネクタ―・セラピュ―ティクスNKTRのチャート
NKTRの企業情報
| symbol | NKTR |
|---|---|
| 会社名 | Nektar Therapeutics （ネクタ―・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ネクター・セラピューティクス（Nektar Therapeutics）は医薬品を発見・開発するバイオ医薬品企業である。同社の新規治験薬の研究開発パイプラインには、がん、自己免疫疾患、慢性疼痛の治療が含まれる。同社は化学物質のプラットフォームを活用して新薬の候補を発見・設計する。薬物候補は既知の作用機序を標的とする新しい分子実体の開発を可能にするように設計されたポリマーコンジュゲート技術プラットフォームを利用する。同社のプログラムには、免疫腫瘍学（I-O）、免疫学、Pain-NKTR-181、および腫瘍学ONZEALDが含まれる。同社は細胞傷害性T細胞やナチュラルキラー（NK）細胞などの主要な免疫細胞の活性を直接的または間接的に調節してその数を増やし、癌細胞を認識して攻撃する機能を改善するように設計された医薬品を開発する。 ネクタ―・セラピュ―ティクスは、米国の医薬品開発会社。PEG化と高度なポリマ―接合体技術プラットフォ―ムを利用し、薬剤を開発。同社の薬剤候補ナロキセゴ―ルは、オピオイド誘発性便秘の治療に使われる経口末梢性オピオイド拮抗薬で、非癌性疼痛をもつ患者に使われる。その他、「Etirinotecanペゴル」、「NKTR-181」などがある。 Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. |
| 本社所在地 | 455 Mission Bay Boulevard South San Francisco CA 94158 USA |
| 代表者氏名 | Robert B. Chess ロバートB.チェス |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 415-482-5300 |
| 設立年月日 | 33055 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 509人 |
| url | www.nektar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nktr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 959.86200 |
| 終値（lastsale） | 51.79 |
| 時価総額（marketcap） | 8932157753.67 |
| 時価総額 | 時価総額（百万ドル） 8261.254 |
| 売上高 | 売上高（百万ドル） 1374.129 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6683.524 |
| 当期純利益 | 当期純利益（百万ドル） 902.71300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Nektar Therapeutics revenues increased from $59.3M to $1.13B. Net income totaled $875.7M vs. loss of $123.7M. Revenues reflect License collaboration and other increase from $10.9M to $1.08B Royalty revenue increase of 34% to $19.6M Non-cash royalty revenue related to sale increase of 20% to $16M. Net Income reflects Other income (expense) net increase from $1.6M to $13.7M (income). |
NKTRのテクニカル分析
NKTRのニュース
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR) 2023/02/01 14:42:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Nektar Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169
Can you now get a good deal on Nektar Therapeutics’s shares? 2023/01/25 16:00:00 US Post News
Nektar Therapeutics (NASDAQ:NKTR) closed Tuesday at $2.27 per share, up from $2.24 a day earlier. While Nektar Therapeutics has overperformed by 1.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NKTR fell by -79.27%, with highs and lows ranging from $11.59 to $1.99, whereas the simple […]
Investing in Nektar Therapeutics (NKTR) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/11 16:40:00 US Post News
The share price of Nektar Therapeutics (NASDAQ:NKTR) rose to $2.42 per share on Tuesday from $2.36. While Nektar Therapeutics has overperformed by 2.54%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NKTR fell by -80.91%, with highs and lows ranging from $12.76 to $1.99, whereas the […]
Nektar Therapeutics (NASDAQ:NKTR) 10.00% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.22? 2023/01/07 14:00:00 Marketing Sentinel
In last trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 1.07 million shares changing hands with its beta currently measuring 1.04. Company’s recent per share price level of $2.42 trading at $0.03 or 1.26% at ring of the bell on the day assigns it a market valuation of $442.76M. That closing price of NKTR’s stock is at … Nektar Therapeutics (NASDAQ:NKTR) 10.00% Up Over The Last Seven Days. Can The Stock Hit Well Above $0.22? Read More »
Nektar Therapeutics (NKTR) Stock Behavior Is Not Predictable 2023/01/06 16:00:00 Stocks Register
Nektar Therapeutics (NASDAQ:NKTR) concluded the trading at $2.39 on Thursday, January 05 with a rise of 2.14% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.34 and 5Y monthly beta was reading 1.18 with its price kept floating in the range … Nektar Therapeutics (NKTR) Stock Behavior Is Not Predictable Read More »
Do investors need to be concerned about Nektar Therapeutics (NKTR)? 2022/12/29 12:16:00 US Post News
The share price of Nektar Therapeutics (NASDAQ:NKTR) rose to $2.07 per share on Wednesday from $2.03. While Nektar Therapeutics has overperformed by 1.97%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NKTR fell by -86.24%, with highs and lows ranging from $15.42 to $1.99, whereas the […]
Nektar Therapeutics (NASDAQ:NKTR) Reduces -6.90% In A Week: What’s Lifting The Stock? 2022/12/16 14:30:00 Marketing Sentinel
In last trading session, Nektar Therapeutics (NASDAQ:NKTR) saw 1.46 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $2.70 trading at -$0.04 or -1.46% at ring of the bell on the day assigns it a market valuation of $525.64M. That closing price of NKTR’s stock is at … Nektar Therapeutics (NASDAQ:NKTR) Reduces -6.90% In A Week: What’s Lifting The Stock? Read More »
Nektar Therapeutics (NKTR) will benefit from these strategies 2022/11/23 16:16:00 US Post News
Nektar Therapeutics (NASDAQ:NKTR) closed Tuesday at $3.43 per share, up from $3.36 a day earlier. While Nektar Therapeutics has overperformed by 2.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NKTR fell by -70.23%, with highs and lows ranging from $15.94 to $2.96, whereas the simple […]
Nektar Therapeutics: Recovery Seems To Be A Mirage (NASDAQ:NKTR) 2022/11/18 22:50:00 Seeking Alpha
Once bearish sentiment ends, good quality biotech stocks will bounce back, but Nektar Therapeutics probably won''t.
An Analysis Of Nektar Therapeutics (NASDAQ: NKTR), And Its Business Forecast 2022/11/16 16:00:00 Marketing Sentinel
In the last trading session, 2.38 million shares of the Nektar Therapeutics (NASDAQ:NKTR) were traded, and its beta was 1.08. Most recently the company’s share price was $3.92, and it changed around -$0.16 or -3.92% from the last close, which brings the market valuation of the company to $669.61M. NKTR currently trades at a discount … An Analysis Of Nektar Therapeutics (NASDAQ: NKTR), And Its Business Forecast Read More »
How should investors view Nektar Therapeutics (NKTR)? 2022/10/11 15:16:00 US Post News
As of Monday, Nektar Therapeutics’s (NASDAQ:NKTR) stock closed at $3.55, up from $3.53 the previous day. While Nektar Therapeutics has overperformed by 0.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NKTR fell by -79.14%, with highs and lows ranging from $17.91 to $2.96, whereas the […]
Nektar Therapeutics, PureTech End Merger Talks 2022/10/11 06:39:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Nektar Therapeutics has mutually agreed with PureTech Health plc to terminate talks regarding a potential business combination. Nektar reserves the right to make or particip…
PureTech Health Confirms ''Possible'' Merger With Nektar Therapeutics 2022/10/07 15:21:22 Benzinga
PureTech Health plc (NASDAQ: PRTC ) has confirmed that it is in talks about a possible tie-up with Nektar Therapeutics (NASDAQ: NKTR ). In April, Nektar Therapeutics announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including Full story available on Benzinga.com
PureTech Health plunges 21% after confirming proposal from Nektar (NASDAQ:PRTC) 2022/10/07 13:12:04 Seeking Alpha
PureTech Health (PRTC) dropped 20% in premarket trading after it confirmed receiving a non-binding proposal from Nektar Therapeutics (NKTR) to combine.PureTech and Nektar remain…
After A 11.18% Jump In The Last Week, Does Nektar Therapeutics (NASDAQ: NKTR) Still Make Sense To Buy? 2022/10/07 11:00:00 Marketing Sentinel
During the last session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 1.42 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $3.38, reflecting an intraday gain of 0.60% or $0.02. The 52-week high for the NKTR share is $17.91, that puts it down -429.88 … After A 11.18% Jump In The Last Week, Does Nektar Therapeutics (NASDAQ: NKTR) Still Make Sense To Buy? Read More »